logo-loader
LON:SCLP

Scancell Holdings PLC

Receive alerts
Market:
LON
Market Cap:
£32.57 m
Price
£0.07
Change
-3.45%
52 weeks high
13.90
52 weeks low
3.00

Viewing results 1-25 of 105

Finance

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date...

10 hours, 39 minutes ago
Health

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year....

on 1/7/19
Health

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”...

on 13/6/19
Retail & consumer

Immuno-oncology: All you wanted to know but were too afraid to ask

Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers...

on 27/5/19
Health

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology ...

on 20/5/19
Health

Scancell surges after announcing milestone in development of its solid tumours treatment

Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research...

on 20/5/19
Health

Scancell adds six ‘world-leading’ cancer specialists to advisory board ahead of Modi-1 trial

“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications”...

on 10/5/19
Health

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck...

on 25/4/19
Health

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia...

on 8/4/19
Health

Scancell strengthens IP with two “important” patent grants in US and Europe

The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88...

on 20/3/19
Health

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise...

on 12/2/19
Health

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic"....

on 31/1/19
Health

Scancell receives “significant scientific endorsement” for technology

The company teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge...

on 23/1/19
Health

Scancell hires two industry veterans as it gears up for the next development phase

The company has brought in outside research and manufacturing expertise ...

on 21/1/19
Health

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer...

on 30/10/18
Health

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma...

on 24/10/18
Health

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology...

on 25/9/18
Health

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago...

on 9/8/18